Ironwood Pharmaceuticals (IRWD) Liabilities and Shareholders Equity (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $285.1 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 16.86% year-over-year to $285.1 million; the TTM figure through Jun 2026 stood at $1.5 billion (up 7.24% YoY), while the FY2025 annual figure was $396.9 million, up 13.11% from the prior year.
• Liabilities and Shareholders Equity came in at $285.1 million for Q2 2026 at Ironwood Pharmaceuticals, down from $434.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q1 2023 to a low of $285.1 million in Q2 2026.
• Average Liabilities and Shareholders Equity over 5 years is $595.1 million, with a median of $436.7 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity soared 80.76% in 2022 and tumbled 62.02% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.1 billion in 2022, then sank by 57.2% to $471.1 million in 2023, then declined by 25.51% to $350.9 million in 2024, then grew by 13.11% to $396.9 million in 2025, then retreated by 28.16% to $285.1 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $285.1 million in Q2 2026, $434.6 million in Q1 2026, and $396.9 million in Q4 2025.